Published on 22/12/2025
Navigating the Clinical Trial Supply Chain in the Indian Regulatory Context
Introduction
Clinical trial supply chain management is a critical yet often under-discussed component of successful clinical research. In India, the complexity of the supply chain is heightened by regulatory, geographical, and infrastructural variables. From importation and storage to last-mile distribution and reconciliation, managing investigational medicinal products (IMPs) in compliance with Good Clinical Practice (GCP) and Indian regulations is essential for the integrity of any trial.
The Indian regulatory body, the Central Drugs Standard Control Organization (CDSCO), sets forth detailed expectations for investigational product handling, transportation, and documentation. Logistics in India also need to contend with vast geographic diversity, climate control challenges, and varying levels of site preparedness. This article outlines the supply chain journey in the Indian context and highlights best practices and preventive strategies for pharma sponsors, CROs, and trial sites.
Background / Regulatory Framework
The New Drugs and Clinical Trials Rules (NDCTR), 2019 form the backbone of clinical trial regulation in India, including the provisions related to investigational product management. While there is no standalone “Clinical Trial Supply Chain” regulation, several clauses under NDCTR, GSR 227(E), and CDSCO’s guidance documents cover key areas of
CDSCO’s Oversight Responsibilities
CDSCO is responsible for issuing licenses for the import of investigational drugs (via Form CT-16 or CT-17), inspecting clinical trial sites, and ensuring that GCP is followed for IMP handling and documentation. In India, no IMP can be distributed for trial use without the proper import license and labeling that complies with Rule 64 of NDCTR.
Applicable Guidelines
- GSR 227(E), NDCTR 2019 – governs labeling, packaging, and distribution of IMPs
- ICMR GCP Guidelines – outlines investigator responsibilities for IMP storage and dispensing
- WHO TRS 961 Annex 9 – provides international guidance on temperature-controlled transport
Core Clinical Trial Insights
1. Importation and Licensing
Import of IMPs into India requires a valid Form CT-16 (for sponsor import) or CT-17 (for investigator-initiated trials). The sponsor must ensure the following:
- Import license is issued by CDSCO before shipment
- IMP is labeled as “For Clinical Trial Use Only” as per Schedule Y
- Customs clearance is facilitated through an authorized freight forwarder
Any deviation from import protocols can result in quarantine of the product and significant trial delays.
2. Depot and Storage Requirements
IMPs are typically stored at central depots before being distributed to clinical trial sites. Key requirements include:
- Storage facilities must be GMP-compliant and validated for temperature and humidity controls
- 24/7 temperature monitoring systems with alarm triggers
- Documented SOPs for receipt, storage, and dispatch
Many multinational trials partner with third-party logistics providers with depots in Mumbai, Hyderabad, or Delhi, depending on import location and site proximity.
3. Labeling and Packaging Compliance
IMPs used in Indian trials must comply with labeling rules under Rule 64 of NDCTR:
- Generic name, protocol number, and batch number
- Date of manufacture and expiry or retest date
- Statement: “For Clinical Trial Use Only”
Labels must be in English or the local language, depending on site requirements. Secondary packaging should also consider transport resilience for the Indian climate.
4. Cold Chain and Transport Logistics
Temperature-sensitive IMPs must be transported in validated containers with continuous monitoring:
- Use of GPS-enabled data loggers
- Pre-qualified cold boxes and shippers
- Real-time tracking and temperature excursion alerts
Transport validation reports are often requested by CDSCO during inspections and must be maintained as part of the Trial Master File (TMF).
5. Site Delivery and Reconciliation
Each site must document receipt of IMPs using Chain of Custody logs. Additional requirements include:
- Site-level storage as per product label
- Temperature mapping for site storage areas
- IMP accountability logs signed by the principal investigator (PI)
At trial completion, unused stock must be returned to the sponsor or destroyed under documented procedures approved by the ethics committee and CDSCO.
6. Risk Management in Supply Planning
India’s unpredictable weather, customs clearance variability, and remote site access can impact IMP availability. Sponsors must develop contingency plans, including:
- Buffer stock at regional depots
- Secondary courier options for emergency shipments
- Proactive tracking systems with alert thresholds
Using centralized forecasting models can improve site-level demand accuracy and reduce wastage.
7. Digitalization and Inventory Tracking
Electronic systems such as Interactive Response Technologies (IRT) and Clinical Trial Supply Management (CTSM) software help monitor stock levels, batch assignments, and expiry tracking. Many CROs and sponsors in India are transitioning to real-time dashboards to meet global supply chain standards.
Best Practices & Preventive Measures
- Start import license applications at least 6–8 weeks before first patient first visit (FPFV)
- Use only validated transport and storage vendors with experience in clinical trials
- Develop clear SOPs for IMP handling, transport, and destruction
- Train site personnel in GCP-compliant drug accountability procedures
- Pre-qualify storage conditions at all sites before IMP dispatch
Scientific & Regulatory Evidence
- NDCTR, 2019 (Rule 64 & 70): Guidelines for import, storage, and distribution of investigational products
- ICMR GCP Guidelines, 2017: Responsibilities of the investigator and sponsor regarding IMP handling
- WHO TRS 961 Annex 9: Guidelines on temperature-controlled transport of pharmaceutical products
- CDSCO FAQs on Clinical Trials: Clarifications on IMP import, labeling, and documentation
Special Considerations
Remote and Tier-2 City Sites: Logistics in remote or underserved areas (e.g., North-East, central tribal belts) need special attention due to lack of storage infrastructure and power backup.
Multi-site Trials: Synchronizing IMP availability across diverse sites requires advanced planning and real-time inventory control systems.
Decentralized Trials: Emerging DCT models in India require patient-centric shipping, which adds layers of complexity in terms of packaging, patient safety, and compliance documentation.
When Sponsors Should Seek Regulatory Advice
- If the IMP includes genetically modified organisms or biologics
- When importing unapproved drugs from non-traditional sources
- To clarify import license requirements for academic or investigator-initiated studies
- For advice on stability data needed for cold-chain management in Indian settings
FAQs
1. Do Indian regulations mandate temperature-controlled transport?
Yes. NDCTR requires IMPs to be handled as per label conditions. WHO and ICMR guidelines support cold chain integrity through validated transport.
2. Is CDSCO approval required for destruction of IMPs?
Yes. Destruction must follow an approved protocol and be documented with ethics committee and CDSCO oversight.
3. Can labeling be done in India post-import?
Yes, but it requires prior CDSCO approval, and the relabeling facility must be GMP compliant.
4. What happens in case of temperature excursion?
Excursions must be reported, investigated, and justified. Impact on IMP stability must be documented and assessed by QA.
5. Can sponsors directly ship to sites without a central depot?
Yes, but it increases the risk and requires robust tracking and temperature validation systems. It is not recommended for high-risk products.
Conclusion
Managing the clinical trial supply chain in India requires a combination of regulatory compliance, logistical precision, and local expertise. With the right planning and partnerships, sponsors can ensure product integrity, regulatory adherence, and successful trial execution across diverse Indian regions.